07:03 AM EDT, 06/26/2025 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) on Friday said its third-quarter net loss widened.

Third quarter net loss of $4.2 million or $0.05 per share compares with last year's loss of $3.7 million or $0.05 per share.

The loss was relatively unchanged due to offsetting variances in G&A and R&D expenditures, the company said.

Medicenna reported cash and cash equivalent balance of $30 million (excluding the $1.9 million that was raised following recent warrant exercises), maintaining its runway through mid-2026